Arch Biopartners (ACHFF) Stock Statistics & Valuation Metrics
Total Valuation
Arch Biopartners has a market cap or net worth of $41.87M. The enterprise value is $56.39M.
- Market Cap
- $41.87M
- Enterprise Value
- $56.39M
Share Statistics
Arch Biopartners has 67,933,290 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 67,933,290
- Owned by Insiders
- 16.48%
- Owned by Institutions
- ―
Financial Efficiency
Arch Biopartners’s return on equity (ROE) is 0.40 and return on invested capital (ROIC) is 145.70%.
- Return on Equity (ROE)
- 0.40
- Return on Assets (ROA)
- -14.85
- Return on Invested Capital (ROIC)
- 145.70%
- Return on Capital Employed (ROCE)
- 0.39
- Revenue Per Employee
- 0
- Profits Per Employee
- -258.79K
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Arch Biopartners is -20.47. Arch Biopartners’s PEG ratio is 0.32.
- PE Ratio
- -20.47
- PS Ratio
- 0.00
- PB Ratio
- -14.83
- Price to FCF
- -34.40
- Price to Operating Cash Flow
- -34.40
- PEG Ratio
- 0.32
Income Statement
In the last 12 months, Arch Biopartners had revenue of 0 and earned -1.55M in profits. Earnings per share was -0.02.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -1.52M
- Pretax Income
- -1.55M
- Net Income
- -1.55M
- EBITDA
- -1.29M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -1.72M and capital expenditures 4, giving a free cash flow of -1.72M billion.
- Operating Cash Flow
- -1.72M
- Free Cash Flow
- -1.72M
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Arch Biopartners pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.91%
- Earnings Yield
- -4.78%
Stock Price Statistics
- Beta
- 0.34
- 52-Week Price Change
- -17.44%
- 50-Day Moving Average
- 0.61
- 200-Day Moving Average
- 0.54
- Relative Strength Index (RSI)
- 54.81
- Average Volume (3m)
- 20.75K
Important Dates
Arch Biopartners upcoming earnings date is Feb 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Feb 02, 2027
- Ex-Dividend Date
- ―
Financial Position
Arch Biopartners as a current ratio of 0.03, with Debt / Equity ratio of -73.16%
- Current Ratio
- 0.03
- Quick Ratio
- 0.03
- Debt to Market Cap
- 0.03
- Net Debt to EBITDA
- -2.19
- Interest Coverage Ratio
- -5.88
Taxes
In the past 12 months, Arch Biopartners has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Arch Biopartners EV to EBITDA ratio is -23.93, with an EV/FCF ratio of -35.99.
- EV to Sales
- 0.00
- EV to EBITDA
- -23.93
- EV to Free Cash Flow
- -35.99
- EV to Operating Cash Flow
- -35.99
Balance Sheet
Arch Biopartners has $2,914.00 in cash and marketable securities with $2.73M in debt, giving a net cash position of -$2.72M billion.
- Cash & Marketable Securities
- $2,914.00
- Total Debt
- $2.73M
- Net Cash
- -$2.72M
- Net Cash Per Share
- -$0.04
- Tangible Book Value Per Share
- -$0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Arch Biopartners is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -15.91%
Scores
- Smart Score
- 7
- AI Score
- ―
